Discovery Fast Track European Challenge.This Challenge is now closed. To be kept informed about future Challenges, sign up below for Challenge News.

Collaborate with GSK drug discovery scientists.

Your idea. Our resources.

Do you have a drug discovery concept? Are you a principal investigator affiliated with a European¹ research institute, college or university? Are you excited about partnering with a leading pharmaceutical company to translate your novel science into a new medicine? If so, the Discovery Fast Track Challenge is for you.

A winning concept.

Tell us about your concept. Our expert panel of judges will evaluate each submission, selecting up to twelve winners between our European and North American challenges. If your concept is chosen, a team of GSK scientists will collaborate with you to screen your target in the same way as we do for internal projects. We will share key results from the screen to provide you with high-quality chemical probes to allow further exploration of the target towards a potential new medicine.

Winners will benefit in multiple ways.

  • We will test our compound collection using our screening platforms to discover active compounds.
  • Together, GSK and the investigator will triage and interpret the data output to identify and confirm chemical probes.
  • We may provide chemical structures of selected chemical probe(s) to investigators to help further their research and potentially lead to high-impact publications (subject to GSK’s existing internal and external obligations)².
  • Promising results may lead to an opportunity for the investigator and institution to collaborate with us to create a novel medicine with the Discovery Partnerships for Academia (DPAc) team.

To get started, create your Discovery Fast Track account.

¹Eligible European countries include: Albania, Andorra, Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Iceland, Ireland, Italy, Hungary, Kosovo, Latvia, Lithuania, Liechtenstein, Luxembourg, Macedonia, Malta, Monaco, Montenegro, Netherlands, Norway, Poland, Portugal, Romania, San Marino, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey, United Kingdom, Vatican City.

²Subject to GSK’s existing internal and external obligations’ means that GSK has no other GSK R&D programs working on the compound and that the compound is not bound by an external collaboration agreement between GSK and a third party, whereby GSK is not permitted to transfer or relinquish these compounds.